X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare STRIDES PHARMA SCIENCE with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs DR. REDDYS LAB - Comparison Results

STRIDES PHARMA SCIENCE    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE DR. REDDYS LAB STRIDES PHARMA SCIENCE/
DR. REDDYS LAB
 
P/E (TTM) x 51.8 26.4 196.2% View Chart
P/BV x 1.1 3.3 34.7% View Chart
Dividend Yield % 0.4 0.8 53.2%  

Financials

 STRIDES PHARMA SCIENCE   DR. REDDYS LAB
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
DR. REDDYS LAB
Mar-18
STRIDES PHARMA SCIENCE/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,1472,788 41.1%   
Low Rs6421,902 33.8%   
Sales per share (Unadj.) Rs317.2860.8 36.9%  
Earnings per share (Unadj.) Rs7.857.1 13.7%  
Cash flow per share (Unadj.) Rs25.1122.0 20.5%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.20.9 26.2%  
Book value per share (Unadj.) Rs274.3757.7 36.2%  
Shares outstanding (eoy) m89.50165.91 53.9%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.82.7 103.5%   
Avg P/E ratio x114.041.1 277.5%  
P/CF ratio (eoy) x35.719.2 185.7%  
Price / Book Value ratio x3.33.1 105.4%  
Dividend payout %25.535.0 72.7%   
Avg Mkt Cap Rs m80,058389,034 20.6%   
No. of employees `0002.523.5 10.7%   
Total wages/salary Rs m4,34132,149 13.5%   
Avg. sales/employee Rs Th11,325.86,070.8 186.6%   
Avg. wages/employee Rs Th1,731.41,366.6 126.7%   
Avg. net profit/employee Rs Th280.1402.5 69.6%   
INCOME DATA
Net Sales Rs m28,394142,810 19.9%  
Other income Rs m9411,552 60.6%   
Total revenues Rs m29,334144,362 20.3%   
Gross profit Rs m3,96523,512 16.9%  
Depreciation Rs m1,54010,772 14.3%   
Interest Rs m1,962788 249.0%   
Profit before tax Rs m1,40313,504 10.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-168344 -48.8%   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m974,380 2.2%   
Profit after tax Rs m7029,468 7.4%  
Gross profit margin %14.016.5 84.8%  
Effective tax rate %6.932.4 21.4%   
Net profit margin %2.56.6 37.3%  
BALANCE SHEET DATA
Current assets Rs m24,836104,984 23.7%   
Current liabilities Rs m18,99368,938 27.6%   
Net working cap to sales %20.625.2 81.5%  
Current ratio x1.31.5 85.9%  
Inventory Days Days7174 95.4%  
Debtors Days Days113104 109.5%  
Net fixed assets Rs m34,289104,385 32.8%   
Share capital Rs m895830 107.8%   
"Free" reserves Rs m23,651124,886 18.9%   
Net worth Rs m24,546125,716 19.5%   
Long term debt Rs m15,51325,089 61.8%   
Total assets Rs m65,437225,443 29.0%  
Interest coverage x1.718.1 9.5%   
Debt to equity ratio x0.60.2 316.7%  
Sales to assets ratio x0.40.6 68.5%   
Return on assets %4.14.5 89.5%  
Return on equity %2.97.5 38.0%  
Return on capital %6.99.7 71.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69772,623 21.6%   
Fx outflow Rs m73518,916 3.9%   
Net fx Rs m14,96253,707 27.9%   
CASH FLOW
From Operations Rs m1,87118,030 10.4%  
From Investments Rs m5,826-14,883 -39.1%  
From Financial Activity Rs m-10,157-4,440 228.8%  
Net Cashflow Rs m-2,615-1,236 211.6%  

Share Holding

Indian Promoters % 27.7 25.5 108.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 5.4 700.0%  
FIIs % 8.6 35.3 24.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 25.9 15.3 169.3%  
Shareholders   56,241 75,885 74.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES SHASUN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Oct 1, 2018 | Updated on Oct 1, 2018

Here's an analysis of the annual report of STRIDES SHASUN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES SHASUN LTD. Also includes updates on the valuation of STRIDES SHASUN LTD.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Nov 16, 2018 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - PLETHICO PHARMA COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS